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INT ROD UCT ION
Allogeneic hematopoietic stem cell transplantation (HCT 
[allo-HCT]) is the only curative treatment for several malig-
nant and nonmalignant hematopoietic diseases. Alloreactive 
T cells mediate the beneficial graft-versus-leukemia/lym-
phoma (GvL) effect and detrimental graft-versus-host dis-
ease (GvHD), the main reason for nonrelapse mortality after 
allo-HCT (Welniak et al., 2007; Li and Sykes, 2012). Do-
nor-derived CD4+Foxp3+ regulatory T cells (T reg cells) sup-
press GvHD in preclinical mouse models of allo-HCT, while 
maintaining the antitumoral effects of transplanted conven-
tional T cells (T con cells; Hoffmann et al., 2002; Edinger et 
al., 2003; Trenado et al., 2003; Nguyen et al., 2007; Pierini 
et al., 2015). Co-infusion of human T con cells and T reg 
cells into immunodeficient mice bearing HLA-mismatched 
human leukemia cells resulted in the rejection of the leu-
kemia without the development of GvHD (Martelli et al., 
2014). The positive effects of the use of donor T reg cells 
in the treatment or prophylaxis of GvHD are mirrored in 
clinical studies in which the occurrence of both GvHD and 
tumor relapse were markedly reduced. Nevertheless, the use 
Donor CD4+Foxp3+ regulatory T cells (T reg cells) suppress graft-versus-host disease (GvHD) after allogeneic hematopoietic 
stem cell transplantation (HCT [allo-HCT]). Current clinical study protocols rely on the ex vivo expansion of donor T reg cells 
and their infusion in high numbers. In this study, we present a novel strategy for inhibiting GvHD that is based on the in vivo 
expansion of recipient T reg cells before allo-HCT, exploiting the crucial role of tumor necrosis factor receptor 2 (TNFR2) in 
T reg cell biology. Expanding radiation-resistant host T reg cells in recipient mice using a mouse TNFR2-selective agonist be-
fore allo-HCT significantly prolonged survival and reduced GvHD severity in a TNFR2- and T reg cell–dependent manner. The 
beneficial effects of transplanted T cells against leukemia cells and infectious pathogens remained unaffected. A correspond-
ing human TNFR2-specific agonist expanded human T reg cells in vitro. These observations indicate the potential of our strat-
egy to protect allo-HCT patients from acute GvHD by expanding T reg cells via selective TNFR2 activation in vivo.
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of donor T reg cells is challenging with regard to the numbers 
and purity of the required cells as well as to their stability after 
infusion into allo-HCT recipients. Current study protocols 
are based on the ex vivo expansion of these cells and/or their 
infusion in high numbers (Brunstein et al., 2011; Di Ianni et 
al., 2011; Edinger and Hoffmann, 2011; Veerapathran et al., 
2013; Martelli et al., 2014).
TNF and its receptors TNFR1 and TNFR2 play a cru-
cial role in both GvHD and the GvL reaction (Levine, 2011). 
TNF, through the activation of TNFR1, causes inflammation 
and tissue damage (Feldmann and Maini, 2003; Chopra et 
al., 2015), whereas the activation of TNFR2 exerts immune- 
suppressive functions (Robinson et al., 2001; Ramos-Casals et 
al., 2008; Ko et al., 2009). TNF affects both mouse and human 
T reg cells, with TNFR2 being a decisive factor (Valencia 
et al., 2006; Chen et al., 2007, 2008; Lin et al., 2008; Grin-
berg-Bleyer et al., 2010; Nagar et al., 2010; Nie et al., 2013; 
Okubo et al., 2013). The TNF–TNFR2 interaction is crucial 
for T reg cell–mediated effects in various mouse models, in-
cluding autoimmune-mediated colitis (Housley et al., 2011; 
Chen et al., 2013), experimental autoimmune encephalomy-
elitis (Tsakiri et al., 2012), and the growth of B16F10 mouse 
melanoma pulmonary metastases (Chopra et al., 2013a).
We developed a novel protein agonist (selective mouse 
TNF-based agonist of TNF receptor 2 [STAR2]) that selec-
tively activates mouse TNFR2 and expands and activates nat-
ural T reg cells (nT reg cells) in vitro and in vivo. The human 
TNF-based counterpart of this agonist expanded human 
T reg cells in vitro. Treatment of recipient mice with STAR2 
before allo-HCT expanded host-type radiation-resistant T reg 
cells and resulted in a significantly improved outcome after 
allo-HCT and prolonged survival without inhibiting the an-
tileukemia or antiinfective effects of transplanted T con cells.
RES ULTS
STAR2 is a highly active mouse TNF-based agonist  
of TNFR2 devoid of TNFR1 stimulatory activity
TNFR2 is highly expressed on T reg cells, and its activation 
has been associated with the expansion and enhanced func-
tion of this cell type (Chen et al., 2007; Housley et al., 2011; 
Chopra et al., 2013a; Okubo et al., 2013). We were therefore 
interested in experimentally evaluating in preclinical in vivo 
models of allo-HCT the idea that TNFR2 targeting induces 
T reg cell expansion and protection from GvHD. Both sol-
uble and membrane-bound TNF can bind to TNFR2, but 
only the membrane-bound form efficiently activates TNFR2 
(Grell et al., 1995). It has, however, been demonstrated that 
oligomerized soluble TNF molecules acquire a high mem-
brane TNF-like TNFR2 stimulatory activity (Schneider et al., 
1998; Rauert et al., 2010). As the available human TNF-based 
TNFR2-specific TNF muteins cannot be used in mice be-
cause of the species specificity of the TNF–TNFR2 interac-
tion, we constructed a nonameric TNFR2-specific variant of 
mouse TNF (STAR2) by fusing a single-chain mouse TNF 
trimer to the trimerization domain of chicken tenascin C 
(TNC; Fig. 1 A). TNFR2 specificity was accomplished by a 
steric clash between STAR2 and mouse TNFR1 as the result 
of two amino acid exchanges (D221N and A223R) within 
the individual TNF subunits (Fig. 1 B). The introduction of 
the TNC trimerization domain into the STAR2 molecule 
causes spontaneous oligomer formation to mimic mem-
brane-bound TNF (Fig. 1 C).
Both wild-type mouse TNF and STAR2 were able to 
bind to mouse TNFR2 (Fig. 1 D), whereas only the wild-
type form but not STAR2 also interacted with TNFR1 
(Fig. 1 E). Human TNF, which only activates mouse TNFR1 
but not TNFR2 (Lewis et al., 1991), inhibited the bone mor-
phogenetic protein 2 (BMP2)–induced production of al-
kaline phosphatase (ALP) in mouse preosteoblastic C2C12 
cells, whereas STAR2 failed to do so (Fig. 1 F). A nonameric 
wild-type variant of mouse TNF, but not STAR2, reduced 
the viability of mouse L929 cells, which are highly sensitive 
to TNFR1-induced cell death (Fig. 1 G). However, STAR2 
efficiently killed cells from a TNFR1/2-deficient immortal-
ized embryonic mouse fibroblast line that was reconstituted 
with a chimeric receptor, in which the extracellular domain 
of the death receptor CD95 was replaced by mouse TNFR2 
(Fig. 1 H). Altogether, these in vitro studies confirmed the 
TNFR2-specific activity of STAR2 expected based on the 
initial binding studies.
STAR2 expands and activates T reg cells in mixed 
T cell cultures in vitro
We isolated splenic T cells from healthy young adult mice 
and incubated them with STAR2 in the absence of any other 
T cell stimulatory factors. Selective TNFR2 activation with 
STAR2 expanded CD4+Foxp3+ T reg cells from wild-type 
but not TNFR2-deficient mice (Fig. 2, A and B). This was 
observed in both CD4+/CD8+ T cell cultures (Fig. 2, A and 
B) and in purified CD4+ T cell cultures of different mouse 
strains (Fig. 2 C). The increase in relative numbers of T reg 
cells in the cultures was accompanied by increased prolifer-
ation of these cells but not of T con cells, as demonstrated 
by CFSE dilution. T reg cells deficient for TNFR2 did not 
proliferate in response to STAR2 treatment (Fig. 2 D). We 
observed a preferential up-regulation of activation mark-
ers CD103, inducible T cell co-stimulator (ICOS), CD69, 
and CD44 on T reg cells upon STAR2 treatment. ICAM-1 
was induced on both T reg cells and T con cells, but on the 
latter cells to a far lesser degree. CD44 on T con cells was 
down-regulated by STAR2 (Fig. 2 E).
To evaluate the relevance of IL-2 for TNFR2-mediated 
T reg cell expansion, we treated isolated CD4+ T cells with 
STAR2, IL-2, rapamycin, and various combinations of these 
reagents. STAR2 and IL-2 expanded T reg cells to a similar 
extent and showed no additive effect. Rapamycin enhanced 
IL-2–induced T reg cell expansion but showed no effect on 
STAR2-induced T reg cell expansion (Fig.  2  F). Treating 
T cells with STAR2 in the presence of IL-2–blocking anti-
bodies ablated the T reg cell–expanding effect of TNFR2 ac-
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Figure 1. STAR2 is a selective agonist for TNFR2. (A) Three linker-connected mouse TNF(D221N-A223R) protomers were fused to the trimerization do-
main of chicken TNC, resulting in the formation of the STAR2 molecule with three covalently linked TNF trimers. F, Flag tag; L, linker; TACE, TNF-α converting 
enzyme; TM, transmembrane domain. (B) Homology model of the extracellular part of mouse TNF (mTNF) bound to the ectodomain of mouse TNFR2 (over-
view; left). The arginine side chain introduced at position 223 of STAR2 fits into mouse TNFR2 (middle) but leads to a steric clash with mouse TNFR1 (right). 
(C) Soluble trimeric TNF binds to but does not properly activate TNFR2, whereas membrane-bound TNF binds to and activates TNFR2. Both soluble and 
membrane-bound TNF bind and activate TNFR1 (not depicted). Nonameric STAR2 binds to and activates only TNFR2 because of mutations preventing TNFR1 
binding. (D) Binding assay for mouse TNFR2. Hek293 cells were transiently transfected with mouse TNFR2 and incubated with a GpL fusion protein of mouse 
TNF and STAR2. (E) Binding assay for mouse TNFR1. Immobilized (immo.) Fc–mouse TNFR1, an Fc fusion protein containing the ectodomain of mouse TNFR1, 
was incubated with GpL–mouse TNF and GpL-STAR2. n.d., not determined. (D and E) Representative data are from two independent experiments. RLU, 
relative light units. (F) Mouse preosteoblastic C2C12 cells were treated with BMP2 in the presence and absence of STAR2 and human TNF (hTNF) before the 
BMP2-induced production of ALP was determined. Rel., relative. (G) Mouse L929 cells were challenged with nonameric wild-type TNF and STAR2. Viability 
was determined by crystal violet staining. (H) Immortalized mouse TNFR1–TNFR2 double KO (DKO) embryonic fibroblasts expressing a chimeric receptor of 
the mouse TNFR2 ectodomain and the intracellular part of human CD95 were stimulated in 96-well plates in triplicates with nonameric wild-type TNF and 
STAR2. Viability was determined by crystal violet staining. (F–H) Data are mean ± SEM of triplicates and are representative of two independent experiments.
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Figure 2. STAR2 expands and activates T reg cells in vitro. (A) Wild-type or TNFR2 KO B6 CD4+/CD8+ T cells were treated with 1.67 nM STAR2 for 96 h 
and analyzed for CD4 and Foxp3 expression. Representative data are from five independent experiments. (B) B6.Foxp3.Luci.DTR-4 CD4+/CD8+ T cells were 
treated with STAR2 for 96 h and analyzed for CD4 and Foxp3-eGFP expression. Combined data are from six independent experiments. (C) CD4 T cells were 
purified from spleens of B6 (n = 6), BALB/c (n = 6), and FVB/N (n = 3) mice and treated with STAR2 for 96 h. The frequency of T reg cells among CD4 T cells 
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tivation. Importantly, blocking IL-2 in the absence of STAR2 
also significantly reduced T reg cell percentages in the cul-
tures, and STAR2 significantly increased these numbers 
(Fig.  2, G and H). Interestingly, treatment of mixed CD4+ 
T con cell/T reg cell cultures with IL-2 but not STAR2 
increased STAT5 phosphorylation in T reg cells but not in 
T con cells (Fig. 2 I). Blocking IL-2 did not affect the induc-
tion of activation markers on T reg cells by STAR2 (Fig. 2 J) 
despite the strong inhibiting effect of IL-2 blockade on T reg 
cell expansion and proliferation.
A recent study has demonstrated that TNFR2 activation 
results in IL-2 expression in CD4+ T cells (Miller et al., 2015), 
and our results indicate that IL-2 may be required for some 
but not all of the effects of STAR2 observed on T reg cells in 
vitro. Future studies must show whether T reg cell expansion 
by STAR2 is merely dependent on the presence of constitu-
tively produced IL-2 present in the T cell culture models used 
here or whether it actively triggers IL-2 production in T reg 
cells and/or T con cells. The latter are only poorly engaged by 
STAR2, but this does not necessarily rule out a contribution 
of this subset to IL-2 production.
STAR2 expands purified T reg cells but neither modifies  
T reg cell suppressive activity on a per cell basis nor induces 
the conversion of T reg cells from T con cells
We next assessed the effects of STAR2 on purified T reg cells 
in the absence of other cells. TNFR2 activation in purified 
T reg cell cultures induced proliferation as demonstrated by 
[3H]thymidine incorporation (Fig. 3 A) and expanded these 
cells independently of the availability of IL-2 (Fig.  3  B). 
STAR2 induced the expression of CD103, ICAM-1, and 
CD69 on purified T reg cells but not of ICOS or CD44 
(Fig. 3 C), in contrast to its effect in mixed T cell cultures 
(Fig. 2 E). Blocking IL-2 did not affect activation marker ex-
pression in T reg cell cultures, consistent with the results ob-
served in mixed cultures (Fig. 2 J).
Despite inducing T reg cell proliferation in mixed T cell 
cultures, STAR2 did not significantly modulate Foxp3 ex-
pression in treated T reg cells in such cultures when compared 
with untreated cells (Fig. 3, D and E). When using purified, 
STAR2-pretreated T reg cells to suppress the proliferation of 
polyclonally activated T con cells, we could not observe dif-
ferences in the suppressive activity on a per cell basis com-
pared with untreated T reg cells (Fig. 3 F).
The increase in T reg cells observed in our in vitro ex-
periments was furthermore not the result of T reg cell con-
version from naive CD4+ cells (Fig. 3 G, left). Indeed, induced 
T reg (iT reg) cell numbers even decreased significantly in the 
presence of STAR2 (Fig. 3 G, right).
A human TNFR2-specific STAR2 equivalent expands 
human T reg cells in vitro
To test for the effects of selective TNFR2 activation on 
human T reg cells and to prove the potential applicability 
of our strategy to patients, we isolated CD4+ T cells from 
PBMCs of healthy donors and treated the cells in vitro 
with TNC-scTNF(143N/145R), a human TNFR2-specific 
STAR2 equivalent based on human TNF that has been de-
scribed elsewhere in detail (Rauert et al., 2010). These ex-
periments revealed a statistically significant expansion of 
CD4+Foxp3+ T reg cells in human CD4+ T cell cultures, in-
dicating that TNFR2-mediated T reg cell expansion is not 
species specific (Fig. 4 A). Furthermore, immunofluorescent 
staining of large bowel biopsies from allo-HCT patients re-
vealed that the majority of Foxp3+ cells in this GvHD target 
organ express TNFR2 (Fig. 4 B).
STAR2 expands T reg cells in vivo
To assess the effects of our TNFR2 agonist on mouse T reg 
cells in vivo, we treated albino B6.Foxp3.Luci.DTR-4 mice, 
which express firefly luciferase under the control of the Foxp3 
promoter, for 2 wk with STAR2 and observed increased 
T reg cell–derived bioluminescence signals in the whole ani-
mal starting 4 d after the initiation of treatment (Fig. 5 A). Ex 
vivo imaging (Fig. 5 B) and immunofluorescence microscopy 
(Fig. 5, C and D) proved that there were increased T reg cell 
numbers in both secondary lymphoid and peripheral organs 
of STAR2-treated wild-type mice. This included the small 
bowel, one of the major target organs in GvHD (Welniak et 
al., 2007; Li and Sykes, 2012). The STAR2-induced increase 
in T reg cell numbers was not observed in TNFR2-deficient 
mice (Fig. 5 D). STAR2 treatment significantly increased the 
was assessed by flow cytometry. Combined data are from three independent experiments. (D) CD4 T cells were purified from spleens of wild-type, TNF KO, 
TNFR1 KO, TNFR2 KO, or TNFR1/R2 KO B6 mice, stained with CFSE, and treated with STAR2 for 96 h. CFSE dilution in T reg cells and T con cells was assessed 
by flow cytometry. Representative data are from three independent experiments. (E) B6.Foxp3.Luci.DTR-4 CD4+/CD8+ T cells treated with STAR2 for 96 h were 
analyzed for activation marker expression on CD4+Foxp3-eGFP− T con cells and CD4+Foxp3-eGFP+ T reg cells. Representative data are from three indepen-
dent experiments. (F) B6.Foxp3.Luci.DTR-4 CD4 T cells were treated with STAR2, IL-2, and rapamycin alone or in combination for 96 h and analyzed for CD4 
and Foxp3-eGFP expression. Combined data are from four independent experiments. (G) B6.Foxp3.Luci.DTR-4 CD4+/CD8+ T cells were treated with STAR2 in 
the presence or absence of IL-2–blocking antibodies (αIL-2) for 96 h and analyzed for CD4 and Foxp3-eGFP expression. Combined data are from seven in-
dependent experiments. (B, C, F, and G) Data are mean ± SEM. (H) B6.Foxp3.Luci.DTR-4 or BALB/c CD4+/CD8+ T cells were treated with STAR2 in the presence 
or absence of IL-2–blocking antibodies for 96 h and analyzed for proliferation (CellTrace Violet dilution). Representative data are from four independent 
experiments. (I) Wild-type B6 CD4 T cells were treated with STAR2 and IL-2 alone or in combination for 96 h and analyzed for CD4 and Foxp3 expression 
and STAT5 phosphorylation. Representative data are from three independent experiments. (J) B6.Foxp3.Luci.DTR-4 or BALB/c CD4+/CD8+ T cells were treated 
with STAR2 in the presence or absence of IL-2–blocking antibodies for 96 h and analyzed for activation marker expression on CD4+Foxp3-eGFP+ T reg cells. 
Representative data are from four independent experiments. *, P ≤ 0.05; **, P ≤ 0.01, two-tailed unpaired Student’s t test. 
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numbers of Ki67+CD4+Foxp3+ cells in the mesenteric lymph 
nodes, suggesting that it acts by inducing T reg cell prolif-
eration (Fig. 5 E). T reg cells expressed more TNFR2 than 
conventional CD4+ T cells or CD8+ T cells in the spleen and 
small intestine, and the expression of TNFR2 increased on 
T reg cells upon in vivo STAR2 exposure (Fig. 5 F). We also 
tested the effects of STAR2 on the expression of activation 
markers on T reg cells and T con cells and found preferen-
tial up-regulation of CD103, ICAM-1, and CD44 on splenic 
T reg cells after in vivo STAR2 treatment. ICOS expression 
was induced on both T con cells and T reg cells, whereas CD69 
expression was not influenced by STAR2 in vivo (Fig. 5 G).
STAR2 does not confer proinflammatory side effects in 
immunologically naive mice
STAR2 did not activate TNFR1 in vitro (Fig. 1), and it did 
not pronouncedly influence the proliferation and activation 
status of T con cells in vitro or in vivo (Figs. 2 and 5). To 
rule out that our TNFR2 agonist conferred proinflamma-
tory side effects in vivo, we analyzed immunologically naive 
Figure 3. STAR2 expands purified T reg 
cells but neither modifies T reg cell sup-
pressive activity on a per cell basis nor in-
duces the conversion of T reg cells from 
T con cells. (A) [3H]thymidine incorporation 
into purified wild-type B6 T reg cells upon 
STAR2 exposure for 72 h. Data show quadru-
plicate culture of cells pooled from seven mice. 
(B) Purified B6.Foxp3.Luci.DTR-4 CD4+CD25+ 
T reg cells were treated with STAR2 for 96 h 
and quantified by flow cytometry. Combined 
data are from three independent experiments. 
(C) Purified B6.Foxp3.Luci.DTR-4 CD4+CD25+ 
T reg cells were treated with STAR2 in the pres-
ence or absence of IL-2–blocking antibodies 
(αIL-2) for 96 h and analyzed for the expression 
of activation markers on CD4+Foxp3-eGFP+ 
T reg cells. Representative data are from three 
independent experiments. (D) Wild-type CD4+ 
T cells were isolated, labeled with CFSE, and 
either left untreated or treated with 1.67 nM 
STAR2 for 96  h. Cells were analyzed by flow 
cytometry for Foxp3 expression and CFSE dilu-
tion after gating on CD4+ cells. Representative 
data are from three independent experiments. 
(E) B6.Foxp3.Luci.DTR-4 CD4+/CD8+ T cells were 
treated with 1.67 nM STAR2 for 96 h, and the 
T reg cell (CD4+Foxp3-eGFP+) numbers in the 
cultures were assessed by flow cytometry. 
Foxp3-luciferase expression was analyzed by 
BLI, and the luciferase activity mirroring the 
activity of the Foxp3 promoter per cell was 
determined. Combined data are from eight 
independent experiments. (F) Wild-type T reg 
cells were purified, treated overnight with 
STAR2 or left untreated, and then co-cultured 
with CD3/CD28-activated, CFSE-labeled T con 
cells for 72 h to assess the suppressive activ-
ity of T reg cells. Representative data are from 
two independent experiments. (G) CD4+CD25− 
T con cells were stimulated with αCD3, αCD28, 
and IL-2 for 72 h in the presence or absence 
of TGF-β and STAR2. Combined data are from 
three or seven independent experiments. (A, B, 
E, and G) Data are mean ± SEM. *, P ≤ 0.05; 
**, P ≤ 0.01, two-tailed unpaired Student’s t 
test. n.s., not significant.
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mice treated with STAR2. The treatment showed no effect 
on other lymphocyte subsets besides T reg cells, whereas it 
changed the composition of the myeloid compartment in the 
spleen and lungs (Fig. 6 A). Importantly, STAR2 application 
over the course of 2 wk had no effect on body weight (bw; 
Fig. 6 B), and it did not affect serum (Fig. 6 C) or tissue levels 
(Fig. 6 D) of IL-6, IL-10, MCP-1, IFN-γ, TNF, and IL-12.
STAR2 pretreatment protects allo-HCT–
recipient mice from acute GvHD
Next, we tested whether prophylactic TNFR2 activation–
mediated expansion of T reg cells in allo-HCT recipients 
protects them from acute GvHD. T reg cells have been re-
ported to be highly radiation resistant compared with other 
immune cells (Anderson et al., 2004; Komatsu and Hori, 
2007), and radiation-resistant T reg cells have been reported 
to control chronic GvHD in mice (Komatsu and Hori, 2007). 
Approximately half of the initial T reg cell numbers in lethally 
irradiated albino B6.Foxp3.Luci.DTR-4 mice rescued with 
wild-type bone marrow persisted 3 wk after transplantation 
based on bioluminescence imaging (BLI) of luciferase-ex-
pressing host T reg cells (Fig. 7, A and B) and flow cytom-
etry (Fig.  7  C), demonstrating radiation resistance of these 
cells in our model, too.
STAR2 pretreatment significantly prolonged the sur-
vival of fully MHC-mismatched allo-HCT recipients 
(FVB[H-2q]→C57BL/6[H-2b]; Fig. 7 D), increasing the me-
dian survival from 16 d to >40 d compared with untreated 
recipients. Prolonged survival was associated with reduced 
weight loss (Fig.  7  E) and lower clinical scores (Fig.  7  F). 
However, when host T reg cells were eliminated from al-
bino B6.Foxp3.Luci.DTR-4 mice by diphtheria toxin (DTx) 
treatment before transplantation (Fig. 7, D–F) or when recip-
ient mice were deficient for TNFR2 (Fig. 7, G–I), the protec-
tive effect of STAR2 was completely abrogated. In a second 
MHC-mismatched allo-HCT model (C57BL/6[H-2b]→ 
BALB/c[H-2d]), STAR2-pretreated mice also lived signifi-
cantly longer than control mice (Fig. 7 J), with a median sur-
vival of 21 versus 10 d. They lost less weight after allo-HCT 
(Fig. 7 K) and had lower clinical scores (Fig. 7 L).
STAR2 protects from GvHD by reducing early alloreactive 
donor T cell expansion and tissue destruction without 
modulating myeloid-derived suppressor cells (MDSCs)
BALB/c allo-HCT–recipient mice were transplanted with 
C57BL/6 wild-type bone marrow and luciferase-expressing 
T cells. In vivo and ex vivo BLI revealed significantly re-
duced early donor T cell proliferation and diminished tar-
get organ infiltration in STAR2-pretreated mice compared 
with untreated controls (Fig.  8, A and B). Reduced target 
tissue infiltration by donor T cells was confirmed by immu-
nofluorescence microscopy (Fig.  8  C) and flow cytometry 
(Fig. 8 D). STAR2-pretreated mice exhibited less tissue dam-
age and accordingly also lower pathology scores, especially so 
in the small bowel (Fig. 8 E). These results are in agreement 
with several studies in which donor T reg cells protected 
against GvHD in mouse models by suppressing early donor 
effector T cell proliferation and migration (Hoffmann et al., 
2002; Nguyen et al., 2007).
STAR2 pretreatment did not alter the myeloid com-
partment in either lymphatic or GvHD target organs 6 d after 
transplantation (Fig. 8 F) and did not modify the suppressive 
capacity of MDSCs in the spleen or the small bowel (Fig. 8 G).
STAR2 pretreatment does not interfere with GvL activity 
of transplanted T cells
Next, we tested whether the antitumoral activity of trans-
planted T cells against co-transplanted, luciferase-expressing 
A20 (Edinger et al., 2003) or preexisting IM380 (Chopra et 
al., 2013b) B cell lymphomas was maintained in TNFR2-primed 
recipients, despite the reduced capacity of donor T cells to 
induce lethal GvHD. When mice were transplanted with 
bone marrow only, both lymphoma types grew progressively 
until the mice succumbed to the malignancies (Fig. 9, A, B, 
E, and F). When untreated or STAR2-pretreated mice were 
co-transplanted with allogeneic T cells, tumors were effi-
ciently eradicated in both groups. STAR2-pretreated mice 
were furthermore protected from lethal acute GvHD (me-
dian survival: A20, 38.5 vs. 14.5 d [Fig. 9 B]; IM380, 26 vs. 
18 d [Fig. 9 F]). This protection translated to significantly re-
duced weight loss and lower clinical scores (Fig. 9, C, D, G, 
and H). Our findings correspond to other studies showing 
the elimination of A20 and BCL-1 tumor cells after co-trans-
plantation of GvHD-inhibiting amounts of donor T reg cells 
(Edinger et al., 2003; Nguyen et al., 2007).
STAR2 does not interfere with the immunological clearance 
of pathogens after transplantation
Expansion of T reg cells for GvHD prophylaxis may raise 
the concern that the immune control of opportunistic in-
fections (Marr et al., 2002; Hebart and Einsele, 2004) in 
immunocompromised HCT recipients during immune re-
Figure 4. A human TNFR2-specific STAR2 equivalent expands 
human T reg cells in vitro. (A) Human CD4+ T cells were isolated from 
healthy donor PBMCs and treated with 1.67 nM TNC-scTNF(143N/145R) 
for 96 h. Combined data are from 16 independent experiments and show 
mean ± 95% confidence interval. (B) Large bowel biopsies from allo-HCT 
patients stained for TNFR2 (green) and Foxp3 (red); representative image 
from five patients. Bar, 25 µm.
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Figure 5. STAR2 expands T reg cells in vivo. (A) Albino B6.Foxp3.Luci.DTR-4 mice were treated with 75 µg (416 pM) STAR2 in PBS i.p. on days 0, 2, 4, 
7, 9, and 11. T reg cell numbers were evaluated in vivo using Foxp3-driven luciferase activity. Representative images are from 11 untreated and 9 STAR2-
treated mice. (B) Ex vivo imaging of internal organs: cervical lymph nodes (cLN), thymus (th), heart (h), lungs (lu), kidneys (ki), inguinal lymph nodes (iLN), 
liver (li), stomach (st), pancreas (pa), small bowel (sb), mesenteric lymph nodes (mLN), cecum (ce), large bowel (lb), and spleen (sp). Combined data are from 
11 untreated and 9 STAR2-treated mice from two independent experiments. (C) Representative microphotographs for CD4+Foxp3+ cells in small bowel, 
spleen, and mesenteric lymph nodes of five untreated and three STAR-treated wild-type mice. (D) T reg cells were counted among small and large bowels 
of untreated (n = 5) and STAR2-treated (n = 3) wild-type mice and untreated (n = 4) and STAR2-treated (n = 3) TNFR2 KO mice. Combined data are from 
two independent experiments. (E) Representative microphotographs and quantification of CD4+Foxp3+Ki67+ cells in mesenteric lymph nodes of untreated 
(n = 5) and STAR2-treated (n = 3) wild-type mice. Combined data are from two independent experiments. (F) TNFR2 expression on CD4+ T con cells, T reg 
cells, and CD8+ T cells in the spleen (top and bottom) and the small bowel (bottom only). Representative flow cytometry plots and combined data are from 
two independent experiments with eight untreated and seven STAR2-treated mice. (G) B6 wild-type mice were treated with STAR2 i.p. for 2 wk, and the 
expression of activation-associated surface proteins was assessed by flow cytometry on CD4+Foxp3+ T reg cells and CD4+Foxp3+ T con cells. Combined data 
are from two independent experiments with seven untreated and six STAR2-treated mice. (A, B, and D–G) Data are mean ± SEM. MFI, mean fluorescence 
intensity. *, P ≤ 0.05; **, P ≤ 0.01, two-tailed unpaired Student’s t test.
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constitution could be suppressed. We therefore tested the 
impact of STAR2 pretreatment in mouse models of mouse 
CMV (mCMV; Podlech et al., 2000, 2002) after experimen-
tal HCT. STAR2 pretreatment of HCT recipients did not 
enhance mCMV infection after syngeneic (Fig. 10, A and B) 
or after allogeneic HCT (Fig. 10, D and E) and also had no 
effect on the numbers and the activation status of lung-infil-
trating total and mCMV-specific CD8+ T cells (Fig. 10 C).
DIS CUS SION
Exogenous activation of TNFR2 with the novel mouse 
TNFR2 agonist STAR2 allows the expansion of T reg cells 
in vivo and protects allo-HCT recipients from acute GvHD, 
also sparing antilymphoma and antiinfectious properties of 
transplanted donor T con cells.
T reg cells prevent excessive alloreactive T cell prolifer-
ation in the lymphohematopoietic system. This observation is 
critical for the mechanistic understanding of how T reg cells 
can prevent GvHD but still allow functional immune responses 
against leukemias, lymphomas, and infections (Edinger et al., 
2003; Jones et al., 2003; Trenado et al., 2003; Schneidawind et 
al., 2013, 2014). Of note, leukemias and lymphomas also pri-
marily manifest in the lymphohematopoietic system, and con-
sequently, if T reg cells limit the number of alloreactive effector 
T cells, the alloimmune response can be predominantly con-
tained to this site (Kim et al., 2003; Beilhack et al., 2005, 2008; 
Coghill et al., 2010), and the GvL response can be preserved. 
In settings where there is a relatively high T cell precursor fre-
quency for major and minor alloantigens, expansion of cyto-
toxic T cells is less important for the exertion of GvL responses. 
However, in the opposite scenario (e.g., after vaccination to a 
rare tumor antigen where the T cell precursor frequency is low 
and T cell expansion is required for a biological effect), T reg 
cells appear to suppress these immune-mediated antitumor ef-
fects (Casares et al., 2010; Klages et al., 2010). Therefore, in the 
typical allo-HCT setting, which comprises immune activation, 
e.g., because of host conditioning, often relatively high T cell 
precursor frequencies for major and minor alloantigens and low 
tumor burden (minimal residual disease) appear to be an ideal 
setting to foster T reg cell function for therapeutic benefits.
Figure 6. STAR2 does not confer proinflammatory side effects in immunologically naive mice. (A) B6 wild-type mice were treated with STAR2 i.p. 
for 2 wk, and the immune cell composition of the spleen and the lungs was assessed by flow cytometry. Monocytes were identified as CD11b+Ly6C+Ly6G−, 
neutrophils as CD11b+Ly6C+Ly6G+, splenic macrophages as CD11bdimCD11c−CD14+F4/80hi, interstitial macrophages as CD11b+CD11c−CD14dimF4/80+, and 
alveolar macrophages as CD11b−CD11chiCD14+F4/80+. Combined data are from two independent experiments with five untreated and three STAR2-treated 
mice *, P ≤ 0.05; **, P ≤ 0.01, two-tailed unpaired Student’s t test. (B) bw’s of untreated (n = 30) and STAR2-treated (n = 30) mice. Combined data are 
from six independent experiments. (C) Serum samples were collected from STAR2-treated mice and analyzed by cytometric bead array for cytokine levels 
(untreated, n = 9; and STAR2, n = 9). Combined data are from three independent experiments. (D) Lung, small bowel, and liver samples were collected from 
STAR2-treated mice, homogenized, and analyzed by cytometric bead array for cytokine levels (untreated, n = 6; and STAR2, n = 6). Combined data are from 
two independent experiments. Data are mean ± SEM.
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The positive effects of TNFR2 activation on mouse 
T reg cells are convincing throughout the literature (Chen et 
al., 2007, 2008, 2013; Grinberg-Bleyer et al., 2010; Housley 
et al., 2011; Chopra et al., 2013a), whereas the effects of TNF 
on human T reg cells are less clear. In our present study, we 
show that a human TNFR2 agonist expands human T reg 
cells in vitro. Chen et al. (2010a) reported earlier that TNFR2 
is a marker associated with increased suppression by human 
peripheral blood T reg cells, and recently, it was demonstrated 
that both an agonistic antibody for TNFR2 and a cross-linked 
TNF multimer, which would also activate TNFR1, efficiently 
expanded T reg cells from healthy donors in vitro (Okubo et 
al., 2013; Ban et al., 2015).
Other studies have demonstrated that activation of 
TNFR2 on human T reg cells inhibits their suppressive func-
tions. Nagar et al. (2010) and Valencia et al. (2006) demonstrated 
the activation of  TNFR2 signaling in human T reg cells to in-
hibit the suppression of  T con cell proliferation by these cells. 
Of note, in both studies, the authors used polyclonal stimula-
tion (anti-CD3) to activate the T con cells in culture. Valenica 
et al. (2006) furthermore characterized T reg cells from patients 
with rheumatoid arthritis and found decreased suppression by 
these cells, whereas they observed an increase in the suppres-
sive activity of T reg cells isolated after TNF blocking therapy. 
Similar results were obtained from a different group (Ehren-
stein et al., 2004) showing that TNF blockade in rheumatoid 
Figure 7. STAR2 pretreatment protects allo-HCT recipient mice from acute GvHD. (A–C) Albino B6.Foxp3.Luci.DTR-4 mice were lethally irradiated 
with 9 Gy and transplanted with 5 × 106 B6 wild-type bone marrow cells. *, P ≤ 0.05; **, P ≤ 0.01, two-tailed unpaired Student’s t test. (A) Representative 
in vivo BLI images of Foxp3-driven luciferase activity before and 20 d after syngenic bone marrow transfer from five mice per group are shown. (B, top) 
Representative ex vivo BLI images of Foxp3-driven luciferase activity of internal organs before and 20 d after syngenic bone marrow transfer from five mice 
per group. (Bottom) Quantification of ex vivo BLI data. Combined data are from two independent experiments with five mice per group and show mean 
± SEM. mLN, mesenteric LN; pLN, peripheral LN. (C, left) Representative flow cytometry plots of CD4+Foxp3-eGFP+ cells among live CD45.2+ immune cells 
in the spleen before and 20 d after bone marrow transfer from five mice per group. (Right) Quantification of CD4+Foxp3-eGFP+ cells among live CD45.2+ 
immune cells in the spleen and small bowel. Combined data are from two independent experiments with five mice per group and show mean ± SEM. 
(D–F) Albino B6.Foxp3.Luci.DTR-4 mice and their wild-type littermates (H-2b) were treated with STAR2 i.p. for 2 wk and injected with 15 ng DTx/g bw on 
days 2 and 1 before allo-HCT with 5 × 106 FVB/N (H-2q) bone marrow cells and 106 FVB/N (H-2q)-enriched T cells (wild type untreated, n = 10; wild type 
STAR2, n = 10; Foxp3.Luci.DTR-4 untreated, n = 10; Foxp3.Luci.DTR-4 STAR2, n = 9; irradiation control, n = 5; and bone marrow control, n = 5). Combined 
data are from two independent experiments. (D) Survival. (E) Relative weight change. (F) Clinical scoring. (G–I) B6 wild-type and TNFR2 KO mice (H-2b) were 
treated with STAR2 i.p. for 2 wk before allo-HCT with 5 × 106 FVB/N (H-2q) bone marrow cells and 106 FVB/N (H-2q)-enriched T cells (wild type untreated, 
n = 5; wild type STAR2, n = 5; TNFR2 KO untreated, n = 4; TNFR2 KO STAR2, n = 4; irradiation control, n = 5; and bone marrow control, n = 5). Combined 
data are from two independent experiments. (G) Survival. (H) Relative weight change. (I) Clinical scoring. (J–L) BALB/c mice (H-2d) were treated with STAR2 
i.p. for 2 wk before allo-HCT with 5 × 106 B6 (H-2b) bone marrow cells and 106 luc+ B6.L2G85.CD90.1 (H-2b)-enriched T cells (untreated, n = 15; STAR2, n = 
15; irradiation control, n = 10; and bone marrow control, n = 10). Combined data are from three independent experiments. (J) Survival. (D, G, and J) **, P ≤ 
0.01, log-rank test. (K) Relative weight change. (L) Clinical scoring. Data are mean ± SEM.
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Figure 8. STAR2 protects from GvHD by reducing early alloreactive donor T cell expansion and tissue destruction without modulating MDSCs. 
(A–E) BALB/c mice (H-2d) were treated with STAR2 i.p. for 2 wk before allo-HCT with 5 × 106 B6 (H-2b) bone marrow cells and 106 B6.L2G85.CD90.1 
(H-2b)-enriched T cells. (A) Representative in vivo BLI images and quantification of luc+ donor T cell expansion and migration in transplanted mice (un-
treated, n = 15; and STAR2, n = 15). Combined data are from three independent experiments and show mean ± SEM. (B–E) On day 6 after allo-HCT, recipient 
mice were dissected. (B) Internal organs were imaged ex vivo for donor T cell–derived bioluminescence (untreated, n = 5; STAR2, n = 5; and bone marrow 
control, n = 5). Combined data are from two independent experiments. mLN, mesenteric LN. (C) Internal organs were prepared for immunofluorescence 
microscopy for the expression of CD90.1, CD4, and CD8 (untreated, n = 5; and STAR2, n = 5). Combined data are from two independent experiments. 
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arthritis patients reverses the observed suppression defect of 
isolated T reg cells. In a follow-up study, it was demonstrated 
that newly occurring T reg cells after TNF blocking therapy 
are actually iT reg cells and not nT reg cells (Nadkarni et al., 
2007). These results are in line with our own results, i.e., that 
TNFR2 activation induces mouse nT reg cells but inhibits the 
induction of iT reg cells from T con cells. Other investigators 
also demonstrated that TNF blocks iT reg cell conversion in 
mice (Housley et al., 2011; Zhang et al., 2013).
We propose that STAR2 likely affects T reg cells in sev-
eral distinct ways. Some of the effects possibly involve or at 
least require the presence of IL-2 and the help of  T con cells, 
whereas other effects appear to be solely T reg cell intrinsic 
and do not require IL-2. STAR2 expands T reg cells both in 
mixed T cell and purified T reg cell cultures, calling for this 
to be a T reg cell–intrinsic effect. We found the induction of 
activation markers on T reg cells to be independent of the 
presence of IL-2, whereas it is vital for the expansion and 
proliferation of these cells in mixed cultures. The observation 
that STAR2 induces several markers on T reg cells both in the 
presence and absence of T con cells, whereas it only up-reg-
ulates other markers in the presence of T con cells, speaks for 
T con cell support to be involved in this effect. Another rea-
son could as well be that the cell density of in vitro cultures 
plays a role in our observed discrepancies between mixed 
T cell cultures and purified T reg cell cultures (Römer et al., 
2011). The failure of in vitro STAR2-treated T reg cells to be 
more suppressive than untreated T reg cells may be the result 
of the experimental conditions, i.e., that the absence of  T con 
cells prevents the T reg cells from becoming fully activated by 
STAR2. However, it might be that despite up-regulating ac-
tivation markers, the STAR2-treated T reg cells are not more 
functional than untreated cells but that their immunosuppres-
sive effects in our in vivo model are the result of increased 
numbers rather than increased function on a per cell basis.
It is worth noting that TNF blockade is associated with 
the exacerbation of various other autoimmune diseases in 
human patients (Robinson et al., 2001; Ramos-Casals et al., 
2008; Ko et al., 2009), stressing the fact that TNF indeed has 
the potential to act as an immunosuppressive factor, possibly 
depending on the underlying disease and whether nT reg 
cells or iT reg cells are the main immunosuppressive T cells in 
the respective disease setting.
We and others have demonstrated that TNFR2 func-
tions as a co-stimulatory molecule for T reg cells. Chen et al. 
(2010b) have additionally shown that TNFR2 is also expressed 
on a subset of  T con cells and that these cells respond to TNF. 
TCR engagement of  T con cells induces TNFR2 expression, 
indicating that activated T con cells respond more to TNF than 
naive T cells (Chen et al., 2010b). We only detected very weak 
expression of TNFR2 on a subset of CD4 T con cells, and 
TNFR2 activation by STAR2 conferred very minor effects to 
T con cells in terms of activation marker expression and pro-
liferation. Exogenous treatment of healthy mice with STAR2 
did not cause adverse effects, indicating that TNFR2 activation 
in our model does not activate proinflammatory signaling in 
conventional T cells. There could be several reasons for this: (a) 
the low expression of TNFR2 on these cells is not sufficient 
to switch on downstream signaling, (b) T reg cells outcompete 
T con cells for STAR2 in vivo because of their much higher 
TNFR2 expression, or (c) STAR2-expanded and -activated 
T reg cells actively suppress activated T con cells in our model. 
Indeed, the fact that TCR-activated T con cells may robustly 
respond to TNFR2 co-stimulation was the reason why we 
chose to treat allo-HCT recipient mice with STAR2 for 2 wk 
before the actual transplantation to minimize potential effects 
of TNFR2 engagement of allogenically activated T con cells.
Our therapeutic approach using donor T reg cells for 
the preventive treatment of GvHD has further advantages 
over current clinical protocols, as it demands neither Good 
Manufacturing Practice–compliant production nor ex vivo 
expansion of donor cells with the potential risk of func-
tional loss. Furthermore, T reg cells are expanded in vivo 
within GvHD target tissues, as opposed to transplanted 
T reg cells that would first need to home to these sites. 
Human mucosal T reg cells that homed to the intestinal tract 
of patients after allo-HCT expressed TNFR2 and TNC- 
scTNF(143N/145R), a human TNF-based STAR2 variant 
specific for human TNFR2-expanded T reg cells in vitro. 
These observations indicate the potential of our strategy to 
protect allo-HCT patients from acute GvHD by expanding 
TNFR2-positive T reg cells via selective TNFR2 activation 
in vivo. Furthermore, this strategy appears to be beneficial 
for other pathological settings in which elevated numbers 
of T reg cells are desirable, such as autoimmune diseases and 
solid organ transplantation.
(D) Internal organs were prepared for flow cytometry (cells were gated on live CD45.2+ immune cells and analyzed for CD90.1 expression–representing 
donor T cells; untreated, n = 5; and STAR2, n = 5). Combined data are from two independent experiments. (E) Internal organs were assessed for tissue 
damage after hematoxylin/eosin staining (untreated, n = 8; STAR2, n = 8; and bone marrow control, n = 6). Combined data are from three independent 
experiments. (F) B6 wild-type mice (H-2b) were treated with STAR2 i.p. for 2 wk, and MDSCs in the lungs, the small bowel (SB), and spleen were assessed by 
flow cytometry 6 d after allo-HCT with 5 × 106 FVB (H-2q) BM cells and 106 FVB (H-2q) T cells (untreated, n = 3; and STAR2, n = 3). Representative data are 
from two independent experiments. (G) CD11b+ cells were isolated from either the spleen or the small bowel of STAR2-treated B6 mice before (top) or after 
(middle and bottom) allogeneic transplantation. Cells of three animals were pooled for analysis. Triplicates of 3 × 105 lymph node cells from BALB/c mice 
as a source of responder T cells were cultured together with 3 × 104 LPS-matured allogeneic DCs from B6 mice and different numbers of sorted B6 MDSCs. 
After 3 d, cells were pulsed with [3H]thymidine overnight to measure cell proliferation. Representative data are from two independent experiments. Data are 
mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01, two-tailed unpaired Student’s t test.
1893JEM Vol. 213, No. 9
Figure 9. STAR2 pretreatment does not in-
terfere with GvL properties of transplanted 
T cells. (A–E) BALB/c (H-2d) mice were treated 
with STAR2 i.p. for 2 wk before allo-HCT. 
Lethally irradiated mice were injected i.v. with 
105 luciferase-expressing A20 B cell lymphoma 
cells (H-2d) and transplanted with 5 × 106 B6 
(H-2b) bone marrow cells. To induce GvHD, 106 
B6 (H-2b)-enriched T cells were injected i.v. 
(A20 + BM, n = 10; A20 + BM + T cells, n = 10; 
A20 + BM + STAR2, n = 8; and A20 + BM + T 
cells + STAR2, n = 8). Combined data are from 
two independent experiments. (A) Representa-
tive in vivo BLI images. (B) Graphic evaluation 
of BLI images taken from a ventral view. **, P 
≤ 0.01, two-tailed unpaired Student’s t test. 
(C) Survival using log-rank test. (D) Relative 
weight change. (E) Clinical scoring. (F–J) BAL-
B/c (H-2d) mice were treated with STAR2 i.p. 
for 2 wk before allo-HCT. Mice were injected 
i.v. with 105 luciferase-expressing IM380 B cell 
lymphoma cells (H-2d) 6 d before allo-HCT. 
Lethally irradiated mice were transplanted 
with 5 × 106 B6 (H-2b) bone marrow cells. To 
induce GvHD, 106 B6 (H-2b)-enriched T cells 
were injected i.v. (IM380 + BM, n = 7; IM380 
+ BM + T cells, n = 7; IM380 + BM + STAR2, 
n = 7; and IM380 + BM + T cells + STAR2, n = 
7). Combined data are from two independent 
experiments. (F) Representative in vivo BLI 
images. (G) Graphic evaluation of BLI images 
taken from a ventral view. *, P ≤ 0.05, two-
tailed unpaired Student’s t test. (H) Survival 
using log-rank test. (I) Relative weight change. 
(J) Clinical scoring. Data are mean ± SEM.
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In silico modeling of TNF–TNFR interactions
The ligand–receptor complexes of mouse TNF bound to the 
extracellular domains of mouse TNFR1 and mouse TNFR2 
were modeled using the structures of human lymphotoxin-α 
bound to TNFR1 and human TNF bound to TNFR2 as 
templates. In brief, the amino acid sequences of the human 
and mouse TNFR1 ectodomains were aligned using CLU 
STA LW software and the structure of human TNFR1 (PDB 
accession no. 1TNR, chain R). Different amino acids in the 
template were replaced with those of mouse TNFR1 using 
the tool ProteinDesign in the software package Quanta2008 
(MSI Accelrys). Insertions and deletions were modeled man-
ually using main chain torsion angles within the allowed 
areas of the Ramachandran plot. Rotamer searches for the 
side chain torsion angles were performed to minimize clashes 
between side chains of introduced amino acid residues. The 
model structure was refined by energy minimization (500 
steps per minimization run) using the CHA RMM27 all-hy-
drogen force field using only geometric energy terms and 
the conjugate gradient algorithm. First, only hydrogen atoms 
were allowed to move, and then side chain atoms were re-
leased, but the atom movements were restricted by applying a 
harmonic potential of 25 kcal mol−1 Å−2, which was gradually 
lowered (5 kcal mol−1 Å−2 and 0 kcal mol−1 Å−2). Finally, the 
structure was refined by performing a final energy minimi-
zation with only the main chain atoms being restrained by a 
weak harmonic potential (2 kcal mol−1 Å−2). The structures 
of the mouse TNF (PDB accession no. 3ALQ, chain A) and 
mouse TNFR2 (PDB accession no. 3ALQ, chain R) ecto-
domains were obtained accordingly. The binary ligand–recep-
tor complexes were formed by docking the structure models 
onto the structure of the TNF–TNFR complexes of LTα–
TNFR1 and TNF–TNFR2 (PDB accession nos. 1TNR and 
3ALQ, respectively). All models displayed good backbone and 
side chain geometries without bad van der Waals contacts. 
Figure 10. STAR2 does not interfere with the immunological clear-
ance of mCMV infection after transplantation. (A–C) BALB/c (H-2d) 
recipients of syngenic HCT were pretreated with STAR2 for 2 wk and ana-
lyzed 4 wk after HCT and infection. (A) Infectious virus (expressed as PFU) in 
lungs and spleen. (B) Immunohistochemical detection of infected cells (red 
stain) and CD3ε+ infiltrate lymphocytes (black stain) in liver tissue sections. 
Please note that there are no infected red cells visible because the infection 
is controlled in both groups at this point. (Left) Representative images. Bars, 
50 µm. (Middle and right) Quantification of infected cells (middle) and of 
infiltrating CD3ε+ lymphocytes (right). (A and B) Symbols represent individ-
ual mice. Median values are marked (PBS, n = 11; and STAR2, n = 10). Com-
bined data are from two independent experiments. The dotted line shows 
the detection limit. (C) Cytofluorometric quantitation and characterization 
of pulmonary CD8 T cells. (Left) Percentage of CD8 T cells in the lympho-
cyte gate. (Middle) Percentage of viral m164 epitope–specific cells among 
the CD8 T cells. (Right) Percentage of short-lived effector cells among the 
m164 epitope–specific CD8 T cells. Symbols represent three independent 
pools, each composed of cells from three to four mice representing their 
experimental mean. (D and E) BALB/c (H-2d) recipients of allo-HCT (with 
BALB/c-H-2dm2 mice as donors) were pretreated with STAR2 for 2 wk and 
analyzed 18 d after HCT (PBS, n = 8; and STAR2, n = 3). Combined data are 
from two independent experiments. (D) Infectious virus (expressed as PFU) 
in spleen, lungs, salivary glands, and liver. (E) Immunohistochemical detec-
tion and quantification of infected cells (left) and of infiltrating CD3ε+ lym-
phocytes (right). (A–E) Two-tailed unpaired Student’s t test was used. All 
p-values were calculated with Welch’s correction to account for unequal 
variance. Data from exponential growth curves (virus titers and numbers of 
infected cells) were log-transformed for the Student’s t test.
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TNFR2-specific variants of mouse TNF were designed 
using information previously published (Loetscher et al., 
1993) on TNFR2-specific mutants of human TNF and mod-
eling these amino acid exchanges in the models described in 
the previous paragraph.
Cloning and production of recombinant proteins
Expression constructs encoding secretable Flag-tagged 
Gaussia princeps luciferase (GpL)–TNC–mouse TNF and 
Flag-tagged TNC–sc–mouse TNF were generated by in-
frame insertion of amplicons encoding mouse TNF (aa 91–
235) or single-chain mouse TNF (aa 91–235) to the 3′ ends of 
GpL-Flag-TNC and Ig-leader Flag-TNC expression cassettes 
previously cloned into the pCR3 vector. An expression plas-
mid containing a single-chain mouse TNF (aa 91–235) DNA 
cassette in which three mouse TNF (aa 91–235)–encoding 
domains were linked by (GGGS)4 peptide linker–encoding 
sequences served as a template for generating the amplicons 
(provided by P. Scheurich and K. Pfizenmaier, Institute of Im-
munology and Cell Biology, University of Stuttgart, Stuttgart, 
Germany). To obtain the mouse TNFR2–specific variants 
GpL-STAR2 and Flag-tagged STAR2, synthetic genes en-
coding conventional mutant mouse TNF(D221N-A223R) or 
single-chain mutant mouse TNF(D221N-A223R) were ob-
tained from a commercial supplier (Geneart) and inserted into 
the pCR3-based GpL-Flag-TNC and Ig-leader Flag-TNC 
expression vectors. The combined use of the trimerization 
domain of chicken TNC and three peptide linker–connected 
TNF protomers results in the formation of a molecule with 
three covalently linked TNF trimers that, in contrast to con-
ventional trimeric TNF molecules, both binds TNFR2 and 
triggers robust receptor activation.
To produce the TNF variants, HEK293 cells were tran-
siently transfected with the corresponding expression plas-
mids via electroporation with an electroporator (Easyject 
Plus; PeqLab) and cultivated for 5–7 d, supernatants were 
purified using anti-Flag affinity chromatography, and the 
concentrations of the recombinant proteins were determined 
by anti-Flag Western blotting and comparison with a Flag-
tagged standard protein.
Binding studies
To analyze the binding of wild-type mouse TNF and mouse 
STAR2 to mouse TNFR2, HEK293 cells were electropo-
rated with an empty vector or a mouse TNFR2 expression 
plasmid. The next day, transfected cells were seeded into 24-
well plates. After an additional day, the cells were incubated 
pairwise at 37°C for 2 h with increasing concentrations of 
GpL-TNC–mouse TNF and GpL-STAR2, and cell-bound 
luciferase activity was assayed using the Gaussia luciferase 
assay kit (New England Biolabs, Inc.) on a Lucy 2 luminome-
ter (Anthos Labtec Instruments). Specific binding values were 
calculated for the two GpL fusion proteins by subtracting the 
values obtained for empty vector–transfected cells (nonspe-
cific binding) from the corresponding values verified for the 
TNFR2 transfectants. To analyze the binding of wild-type 
mouse TNF and STAR2 to mouse TNFR1, a black high-
bond 96-well ELI SA plate coated with 0.5 µg/ml protein G 
was loaded with 1 µg/ml of an Fc fusion protein of the ecto-
domain of mouse TNFR1. Wells were then incubated with 
increasing concentrations of GpL–mouse TNF and GpL-
STAR2 for 1  h at 37°C, and the well-associated luciferase 
activity was quantified using the Gaussia luciferase assay kit. 
Bmax and Kd values were obtained by fitting the binding data 
by nonlinear regression to a one side–specific binding plot 
using Prism5 (GraphPad Software).
Analysis of cell viability and ALP activity
Cell viability was assessed using standard crystal violet stain-
ing. To measure ALP activity in BMP2-stimulated mouse 
preosteoblastic C2C12 cells, the cells were cultivated for 48 h 
in the presence and absence of TNFR1 and TNFR2 agonists 
in DMEM with 2% FCS. Finally, cells were lysed, and ALP 
activity was determined using p-nitrophenylphosphate con-
version and measuring the absorbance at 405 nm.
Animals
BALB/c, C57BL/6, and FVB/N mice were obtained from 
Charles River. B6.129S7-Tnfrsf1btm1Imx/J (B6.TNFR2 KO), 
C57BL/6-Tnfrsf1atm1lmx/J (B6.TNFR1 KO), B6.129S- 
Tnfrsf1atm1ImxTnfrsf1btm1Imx/J (B6.TNFR1R2 KO), and 
B6.129S6-Tnftm1Gkl/J (B6.TNF KO) (all on a C57BL/6 H-2b 
background) were initially obtained from The Jackson Labo-
ratory. B6(Cg)-Tyrc-2J/J albino C57BL/6 mice were provided 
by B. Holtmann (Center for Experimental Molecular Medi-
cine at the University Hospital Würzburg, Würzburg, Ger-
many). C57BL/6.Foxp3.Luci.DTR-4 mice expressing 
enhanced GFP (eGFP), firefly luciferase, and the human DTx 
receptor under the control of the Foxp3 promoter (Suffner et 
al., 2010) were provided by G. Hämmerling (German Cancer 
Research Center, Heidelberg, Germany). C57BL/6.Foxp3.
Luci.DTR-4 mice were backcrossed to albino B6 to generate 
albino B6.Foxp3.Luci.DTR-4 mice, which are superior to 
black mice in terms of in vivo BLI sensitivity. The genotypes 
of transgenic mice were routinely checked by flow cytometry 
of GFP-expressing PBMCs or standard PCR for B6.TNFR2 
KO mice. B6.L2G85.CD90.1 mice ubiquitously expressing 
firefly luciferase were described previously (Beilhack et al., 
2005). Female mice were used for experiments between 8 
and 12 wk of age. All mice were bred within the specified 
pathogen-free animal facilities of the Center for Experimen-
tal Molecular Medicine at the Würzburg University Hospital 
or in the Central Laboratory Animal Facility at the University 
Medical Center of the Johannes Gutenberg University, Mainz. 
Mice received rodent chow and autoclaved drinking water ad 
libitum. All animal experiments were approved by local au-
thorities (animal ethics committee of the Regierung von Un-
terfranken 55.2–2531.01-12/13; animal ethics committee of 
the Landesuntersuchungsamt Rheinland-Pfalz 177–07/G09-
1-004) and complied with German animal protection laws.
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Cell culture
A20 yellow fluorescent protein (yfp)/luc mouse B cell lym-
phoma (H-2d) cells expressing firefly luciferase and yfp (Edinger 
et al., 2003) and IM380 mouse B cell lymphoma (H-2d) cells 
expressing firefly luciferase and eGFP (Chopra et al., 2013b) 
were maintained in complete RPMI medium and passaged 
twice weekly. Both cell lines are syngeneic to BALB/c mice.
Cell isolation from the bone marrow, spleen, 
lungs, and intestinal tract
Bone marrow cells were isolated from BALB/c, C57BL/6, 
or FVB/N mice. Femur and tibia bones were flushed with 
PBS, and the cell suspension was filtered through a 70-µm cell 
strainer (BD). Spleens were directly filtered through a 70-µm 
cell strainer into erythrocyte lysis buffer (168 mM NH4Cl, 
10 mM KHCO3, and 0.1 mM EDTA). T cells were enriched 
from the splenocytes using the Dynal Mouse T cell Nega-
tive Isolation kit (Invitrogen) according to the manufactur-
er’s instructions. Negative isolated T cells were stained with 
anti-CD25 PE-labeled mAb (PC61; BD), and CD4+CD25+ 
or CD4+CD25− cells were enriched by anti-PE magnetic- 
activated cell-sorting beads (Miltenyi Biotec). Lung and gut 
samples were minced with a surgical blade and digested for 
45 min at 37°C with 2 mg/ml collagenase D and 0.1 mg/
ml DNase I (both from Roche). Tissue pieces were mashed 
through a 70-µm cell strainer and spun down. The cell pellet 
was resuspended in erythrocyte lysis buffer.
Isolation of CD4+ T cells from human PBMCs
Human peripheral blood samples were obtained from 
the Department of Transfusion Medicine at the Univer-
sity Hospital Würzburg, and use of the samples complied 
with the approval of the University Hospital of Würzburg 
Ethical Committee. PBMCs were isolated by standard 
Ficoll gradient centrifugation (Bicoll; Biochrom). CD4+ 
T cells were enriched using a human CD4+ T cell isola-
tion kit (Miltenyi Biotec).
T cell cultures
Enriched T cells were cultured in 96-well round-bot-
tom plates in complete RPMI medium for 96 h. Primary 
CD4+CD25− T con cells were differentiated in IMDM (5% 
FCS; Invitrogen) for 72  h using a combination of plate-
bound αCD3 mAb (145-2C11; 1–5 µg/ml) and αCD28 
mAb (37.51; 1–10 µg/ml; both BD) in the presence of 
50 U/ml recombinant human IL-2 (PeproTech), 2–5 ng/
ml human TGF-β (PeproTech), 5 µg/ml anti–IFN-γ (R&D 
Systems), 5 µg/ml anti–IL-4 (R&D Systems), and 5 µg/ml 
anti–IL-12 (R&D Systems).
Cytometric bead array
Serum and tissue cytokine concentrations were determined 
using a cytometric bead array kit (BD) according to the 
manufacturer’s protocol. Data were analyzed by FCAP Array 
software (version 2.0).
Allo-HCT, GvHD, and GvL models
Host mice were injected i.p. with 75 µg (416 pmol) STAR2 
in 200 µl PBS on days 14, 12, 10, 7, 5, and 3 with respect 
to the day of allo-HCT. To study the influence of T reg cell 
depletion, B6.Foxp3.Luci.DTR-4 mice (untreated or pre-
treated with STAR2 for 2 wk) were injected i.p. with 15 ng/g 
bw DTx in 200 µl PBS on days 2 and 1 in respect to the 
day of transplantation.
Transgenic albino B6.Foxp3.Luci.DTR-4 mice, 
TNFR2 KO mice, and their wild-type littermates were le-
thally irradiated at a dose of 9 Gy using an x-ray irradia-
tion system (CP-160; Faxitron X-Ray) and injected with 
5 × 106 allogeneic bone marrow cells and 106 enriched 
T cells, both isolated from FVB/N donor mice. BALB/c mice 
were lethally irradiated with a dose of 8 Gy and injected with 
5 × 106 allogeneic bone marrow cells isolated from B6 donor 
mice and 106 enriched T cells from luc+ B6.L2G85.CD90.1 
mice. Donor cells in 100 µl PBS were injected i.v. into the 
retro-orbital plexus of irradiated host mice.
For GvL experiments, 105 A20 yfp/luc cells in 100 µl 
PBS were injected into the lateral tail vein of host mice after 
irradiation and the transfer of bone marrow and T cells. For 
the IM380 model, 105 cells were injected into the lateral tail 
vein of host mice 6 d before allo-HCT.
Mice were treated with antibiotic drinking water (Baytril; 
Bayer) for 1 wk to prevent infections after myeloablative irradi-
ation. Transplanted mice were assessed for weight loss and clin-
ical scoring for GvHD and leukemia symptoms (Cooke et al., 
1996) at indicated time points until the end of the experiment.
In vivo BLI
Mice were anesthetized with i.p. injection of 80 mg/kg bw 
esketamine hydrochloride (Pfizer) and 16 mg/kg bw xylazine 
(cp Pharma). Together with anesthetics, mice were injected 
with 300 mg/kg bw d-luciferin (Biosynth). 10 min later, 
bioluminescence signals from the anesthetized mice were re-
corded using an imaging system (IVIS Spectrum; Caliper Life 
Sciences). Pictures were taken in automatic mode with a max-
imum exposure time of 5 min per picture and analyzed using 
Living Image software (version 4.0; Caliper Life Sciences).
Ex vivo imaging, tissue sample preparation, and 
histopathological evaluation
Mice were injected with d-luciferin and euthanized 10 min 
later. Internal organs were removed and subjected to ex 
vivo BLI (Beilhack et al., 2005). Tissue samples were em-
bedded in optimal cutting temperature compound (Tissue 
Tek; Sakura) or stored in 4% paraformaldehyde in PBS for 
further standard hematoxylin/eosin histopathological anal-
ysis and scored for the following endpoints (scores of 0–4 
depending on severity): crypt apoptosis, inflammation, and 
crypt loss in the small and large bowel; bile duct injury, vas-
cular injury, hepatocellular damage, and portal inflammation 
in the liver; and (with scores of 0–3 depending on severity) 
apoptosis, ballooning of the basal layer, and inflammation 
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in the skin. Samples from the spleen and small and large 
bowel were stored in PBS on ice for immune cell isola-
tion and flow cytometry.
Flow cytometry
Cells were blocked with normal rat serum (1:20 in PBS) and 
stained with the appropriate antibodies (Table S1) at 4°C for 
30 min. Cells were stained using fixable live/dead cell stain 
kits (Invitrogen or BioLegend) and antibodies for surface 
antigens and then further processed using a Mouse Regula-
tory T Cell Staining kit (no. 2; eBioscience) according to the 
manufacturer’s protocol. All experiments were analyzed on a 
cell analyzer (FACS Canto II; BD), and the sample data were 
recorded using FAC SDiva software (BD) and analyzed using 
FlowJo software (Tree Star).
Immunofluorescence microscopy
Cryo-embedded tissues were cut into 3-µm-thick sections 
on a cryostat (CM1900; Leica Biosystems) and mounted 
onto frosted slides. The slides were air dried, fixed with ac-
etone at room temperature, washed, and blocked with 2% 
FCS in PBS for 15 min. When biotin-conjugated antibod-
ies were used, additional blocking was performed using an 
avidin/biotin blocking kit (Vector Laboratories). The slides 
were then incubated with the appropriate antibodies (1:100; 
Table S1) for 1 h at room temperature, counterstained with 
DAPI, and mounted with mounting medium (Vector Labora-
tories). Images were obtained with a fluorescence microscope 
(Imager.Z1m; ZEI SS) at room temperature and evaluated 
using AxioVision software (ZEI SS).
For confocal laser-scanning microscopy, paraffin-em-
bedded biopsies of the large bowel from allogeneic-trans-
planted human patients were sectioned, deparaffinized, and 
pretreated with cell stabilizing buffer, pH 6.0. Sections were 
incubated with primary antibodies (rat anti-Foxp3, 1:100; and 
rabbit anti-TNFR2, 1:250; Table S1) for 1 h followed by 
secondary antibodies (1:400) for 1 h. Sections were analyzed 
using a confocal laser-scanning microscope (TCS SP2; Leica 
Biosystems) and confocal software (Leica Biosystems).
Syngeneic HTC/allo-HCT and mCMV infection
Female BALB/c mice were pretreated i.p. with 75 µg (416 
pM) STAR2 in PBS on days 14, 12, 10, 7, 5, and 3 with 
respect to the day of HCT or were treated with PBS for 
control. HCT and mCMV infections were performed with 
both groups as described previously (Podlech et al., 2000). In 
brief, HCT recipients were immunocompromised by mye-
loablative total-body γ irradiation with a single dose of 6.5 
Gy. HCT was performed 6 h later by infusion of 5 × 106 
bone marrow cells derived from either BALB/c (syngeneic 
setting) or BALB/c-H-2dm2 (allogeneic setting; these mice 
lack the MHC class I Ld molecule because of a genetic de-
letion; Rubocki et al., 1986) into the tail vein of the recip-
ients. Intraplantar infection of the recipients with 105 PFU 
of wild-type virus mCMV-WT.Smith (strain Smith ATCC 
VR-1399) was performed 2 h after HCT.
Quantitation of mCMV infection in host tissues
Infectious virus at 18 d (allogeneic setting) or 4 wk (syngeneic 
setting) after HCT and infection was quantitated in organ ho-
mogenates by the virus plaque (PFU) assay on mouse embryo 
fibroblast monolayers (Podlech et al., 2000). mCMV infection 
and T cell infiltration of the liver was assessed by two-color 
immunohistochemistry with red staining of the intranuclear 
viral protein IE1-pp89/76 (mAb clone Croma 101) and black 
membrane staining of CD3ε (mAb clone CD3-12)-express-
ing lymphocytes (Podlech et al., 2000).
Preparation and phenotypic analysis of lung leukocytes
Interstitial pulmonary leukocytes were isolated as previously 
described (Podlech et al., 2000). In brief, lungs were perfused 
via the right ventricle with perfusion solution (PBS + 10 U/ml 
Heparin) and were excised. Tracheae, bronchi, and pulmonary 
lymph nodes were carefully removed, the lobe of the left lung 
was stored for the virus plaque assay (Podlech et al., 2000), 
and the remaining four lung lobes were minced with scissors. 
Digestion of pooled lobes from three to four lungs was per-
formed in 15 ml DMEM + 0.4 U/ml collagenase A (Roche) 
+ 33 U/ml DNase I (Sigma-Aldrich) for 1 h at 37°C with 
constant stirring. Tissue clumps were resolved by straining 
the digested tissue through a steel mesh. Cells were washed 
and passed through a 100-µm nylon mesh, and mononuclear 
leukocytes were enriched by density gradient centrifugation.
For cytofluorometric analysis, leukocytes isolated from 
the lungs of three to four mice per group were labeled with 
an MHC-peptide multimer (dextramer H-2Dd-m164[AGP 
PRY SRI] PE conjugated; 10  µl per 106 cells; catalog no. 
JB3533-PE; Immudex) to detect m164 epitope–specific 
TCRs together with directly fluorochrome-conjugated 
mAbs. Analysis was performed with FC500 and CXP soft-
ware (version 2.2; Beckman Coulter).
Statistical analysis
All data are reported as mean ± SEM and represent combined 
data from at least two independent experiments unless noted 
otherwise. Figures were prepared using Prism 5 (GraphPad 
Software) and Photoshop 7 (Adobe). Different groups were 
compared by two-tailed unpaired Student’s t tests using In-
Stat 3 (GraphPad Software) unless noted otherwise. Signifi-
cance was set at P ≤ 0.05.
Online supplemental material
Table S1 shows the antibodies used in this study. Online 
supplemental material is available at http ://www .jem .org /
cgi /content /full /jem .20151563 /DC1.
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